Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction

Journal of the American College of Cardiology

Volumn 15, Issue 6, 1990, Pages 1385-1393

  Schaer, Gary L ^a   Karas, Steven P ^a   Santoian, Edward C ^a   Gold, Craig ^a   Visner, Marc S ^a   Virmani, Renu ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOSOL DA;

ANIMAL EXPERIMENT; ARTICLE; DOG; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE PERFUSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION;

EID: 0025319096     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(10)80029-4     Document Type: Article

References (57)

1. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction
2. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI phase I) Trial
3. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
5. Myocardial reperfusion: a double edged sword?
6. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo 1, Anti-CD 11b) that inhibits leukocyte adhesion
7. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion
8. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs
9. Iloprost inhibits neutrophil function in vitro and in vivo and limits experiental infarct size in canine heart
10. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog
11. Accumulation of polymorphonuclear leukocytes during 3 hour experimental myocardial ischemia
12. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury
13. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions
14. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog
15. Effects of intravenous fluorocarbons during and without oxygen enhancement on acute myocardial ischemic injury assessed by measurement of intramyocardial gas tensions
16. Maintenance of aerobic metabolism during global ischemia with perfluorocarbon cardioplegia improves myocardial preservation
17. Effect of intracoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions
18. Myocardial protection by perfluorochemical infusion during transient ischemia produced by balloon coronary occlusion
19. Distal coronary artery perfusion during percutaneous transluminal coronary angioplasty
20. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%
21. Dissociation of ST segment elevation and regional wall motion with open-artery, intracoronary Fluosol
22. Beneficial long-term effect of intracoronary perfluorochemical on infarct size and ventricular function in a canine reperfusion model
23. Oxygen consumption and coronary reactivity in post-ischemic myocardium
24. The use of single plane angiocardiograms for the calculation of left ventricular volume in man
25. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique
26. Animal models for protecting ischemic myocardium: results of the NHLB1 cooperative study
27. Tetrazolium is unreliable as an index of drug induced salvage (abstr)
28. Myocardial platelet trapping after coronary ligation in primates
29. Kinetics and imaging of indium 111-labeled autologous platelets in experimental myocardial infarction
30. The interactions of platelet-derived mediators on isolated coronary arteries
31. Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens
32. Platelet-derived growth factor promotes polymorphonuclear leukocyte activation
33. Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium
34. Amphipathic metabolites and membrane dysfunction in ischemic myocardium
35. Role of free radicals in catecholamine-induced cardiomyopathy
36. Effects of dopamine on functional recovery after a reversible ischemic myocardial injury
37. Platelet trapping in myocardial infarct in baboons: therapeutic effect of aspirin
38. The “no reflow” phenomenon after temporary coronary occlusion in the dog
39. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation
40. Canine myocardial reperfusion injury: its reduction by the combined administration of superoxide dismutase and catalase
41. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor)
42. Release of platelet-activating factor from ischemic-reperfused rabbit heart
43. The biologically active leukotrienes
44. Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human Clq in vivo
45. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury
46. Fluorocarbons reduce myocardial ischemic damage after coronary occlusion
47. Effect of fluocarbon exchange transfusion on myocardial infarction size in dogs
48. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion
49. Paralysis of phagocyte migration due to an artificial blood substitute
50. Effects of perfluorochemical on phagocytic function of leukocytes
51. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals
52. Can superoxide dismutase alter myocardial infarct size?
53. Distribution of myocardial injury and its relation to epicardial ST-segment changes after coronary artery occlusion in the dog
54. Electrocardiographic ST-segment analysis in the characterization of myocardial ischemia and infarction
55. Stability of multilead ST-segment “fingerprints” over time after percutaneous transluminal coronary angioplasty and its usefulness in detecting reocclusion
56. The stunned myocardium: prolonged, postishemic ventricular dysfunction
57. Direct vs. sequential percutaneous transluminal coronary angioplasty